Philippe A R R Pijls1, Lennard P L Gilissen2. 1. Department of Gastroenterology and Hepatology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands. Electronic address: philippe.pijls@catharinaziekenhuis.nl. 2. Department of Gastroenterology and Hepatology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands. Electronic address: lennard.gilissen@catharinaziekenhuis.nl.
Abstract
BACKGROUND: The treatment of patients with inflammatory bowel diseases has been revolutionized by the introduction of biological therapy with TNF-alpha blockers. However, TNF-alpha blockers are also associated with a wide variety of dermatological side effects, such as local skin infections, psoriasis and eczema. A new biological therapy, targeting the gut-specific adhesion molecule alpha4beta7 integrin, is the humanized monoclonal IgG1 antibody vedolizumab. Vedolizumab prevents leukocyte migration to the gastrointestinal tract, thereby reducing inflammation. This gut-specific therapy has the potential to reduce systemic side effects, including dermatological ones. METHODS: We describe 3 inflammatory bowel disease patients who experience anti-TNF-alpha therapy-induced dermatological side effects, consisting of hidradenitis suppurativa, a folliculitis, scalp psoriasis and a dissecting folliculitis. RESULTS: In all patients, anti-TNF-alpha therapy-induced dermatological side effects diminished after switching to vedolizumab. CONCLUSION: Vedolizumab may be a viable alternative biological therapy in inflammatory bowel disease patients who experience anti-TNF-alpha therapy-induced dermatological side effects.
BACKGROUND: The treatment of patients with inflammatory bowel diseases has been revolutionized by the introduction of biological therapy with TNF-alpha blockers. However, TNF-alpha blockers are also associated with a wide variety of dermatological side effects, such as local skin infections, psoriasis and eczema. A new biological therapy, targeting the gut-specific adhesion molecule alpha4beta7 integrin, is the humanized monoclonal IgG1 antibody vedolizumab. Vedolizumab prevents leukocyte migration to the gastrointestinal tract, thereby reducing inflammation. This gut-specific therapy has the potential to reduce systemic side effects, including dermatological ones. METHODS: We describe 3 inflammatory bowel diseasepatients who experience anti-TNF-alpha therapy-induced dermatological side effects, consisting of hidradenitis suppurativa, a folliculitis, scalp psoriasis and a dissecting folliculitis. RESULTS: In all patients, anti-TNF-alpha therapy-induced dermatological side effects diminished after switching to vedolizumab. CONCLUSION:Vedolizumab may be a viable alternative biological therapy in inflammatory bowel diseasepatients who experience anti-TNF-alpha therapy-induced dermatological side effects.
Authors: Liege I Diaz; Tara Keihanian; Ingrid Schwartz; Su Bin Kim; Fernando Calmet; Maria Alejandra Quintero; Maria T Abreu Journal: Gastroenterol Hepatol (N Y) Date: 2020-02
Authors: Mark Fleisher; Jan Marsal; Scott D Lee; Laura E Frado; Alyssa Parian; Burton I Korelitz; Brian G Feagan Journal: Dig Dis Sci Date: 2018-02-26 Impact factor: 3.199